E2F4 and acute myeloid leukemia: In addition, E2F4 inhibitors may exert stronger inhibitory and therapeutic effects in AML than EZH2 inhibitors as EZH2 has a contrasting role in AML (during the induction phase, the presence of EZH2 improves survival, and during the maintenance phase, loss of EZH2 helps in survival).